Heim1099 • HKG
add
Sinopharm Group Co Ltd
Við síðustu lokun
20,04 $
Dagbil
20,04 $ - 20,46 $
Árabil
16,74 $ - 22,35 $
Markaðsvirði
63,79 ma. HKD
Meðalmagn
5,13 m.
V/H-hlutf.
8,52
A/V-hlutfall
3,62%
Aðalkauphöll
HKG
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (CNY) | sep. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 145,44 ma. | -1,53% |
Rekstrarkostnaður | 6,37 ma. | -6,94% |
Nettótekjur | 1,85 ma. | 16,88% |
Hagnaðarhlutfall | 1,27 | 18,69% |
Hagnaður á hvern hlut | — | — |
EBITDA | 4,66 ma. | 3,57% |
Virkt skatthlutfall | 24,66% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (CNY) | sep. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 38,77 ma. | — |
Heildareignir | 418,38 ma. | — |
Heildarskuldir | 286,21 ma. | — |
Eigið fé alls | 132,17 ma. | — |
Útistandandi hlutabréf | 3,12 ma. | — |
Eiginfjárgengi | 0,76 | — |
Arðsemi eigna | 2,46% | — |
Ávöxtun eigin fjár | 4,71% | — |
Peningaflæði
Breyting á handbæru fé
| (CNY) | sep. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 1,85 ma. | 16,88% |
Handbært fé frá rekstri | -4,97 ma. | 26,15% |
Reiðufé frá fjárfestingum | 781,72 m. | -19,99% |
Reiðufé frá fjármögnun | -4,04 ma. | -162,10% |
Breyting á handbæru fé | -8,22 ma. | -12,59% |
Frjálst peningaflæði | -1,34 ma. | — |
Um
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Stofnsett
2003
Vefsvæði
Starfsfólk
100.251
